Pharma Mar, S.A. (BME:PHM)

Market Cap	1.60B
Revenue (ttm)	175.75M
Net Income (ttm)	19.88M
Shares Out	17.57M
EPS (ttm)	n/a
PE Ratio	80.64
Forward PE	32.05
Dividend	0.80 (0.88%)
Ex-Dividend Date	Jun 25, 2025

Volume	25,583
Average Volume	50,401
Open	91.40
Previous Close	91.20
Day's Range	89.00 - 91.40
52-Week Range	31.82 - 105.80
Beta	-0.11
RSI	66.35
Earnings Date	Jul 25, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.